Related Experiment Videos
Molecular determinants of UCN-01-induced growth inhibition in human lung cancer cells
1Division of Pharmacology, National Cancer Center Research Institute, Tokyo, Japan.
Abstract:
UCN-01 (7-hydroxystaurosporine) inhibits the growth of various malignant cell lines in vitro and in vivo. In this study, a human small cell lung carcinoma subline resistant to UCN-01, SBC-3/UCN, was established and characterized. SBC-3/UCN cells showed 8-fold greater resistance to the UCN-01-induced growth-inhibitory effect than the parent cells, SBC-3. No UCN-01-induced G1 accumulation in SBC-3 cells was observed in SBC-3/UCN cells and decreased expression of phosphorylated RB protein was found in SBC-3 cells. Neither basal expression nor induction of p21(Cip1) by UCN-01 treatment was detected in the SBC-3/UCN cell line. An inhibitory effect of UCN-01 on CDK2 activity, which is mediated by p21(Cip1)/CDK2 complex formation upon UCN-01 treatment, was observed in SBC-3 but not in SBC-3/UCN cells. SBC-3/UCN showed higher CDK6 activity than SBC-3 cells. UCN-01 did not inhibit the CDK4 and CDK6 activities in both cells. We screened the cell cycle regulatory molecules associated with G(1)/S progression and found a remarked decrease in interferon regulatory factor 1 (IRF-1), which is known to cooperate with p53 in p21(Cip1) induction. Our results suggest that p21(Cip1) regulation via the IRF-1-associated pathway may represent a major determinant of UCN-01-induced growth inhibition in human lung cancer cells.
Insights
UCN-01 resistance in lung cancer cells is linked to reduced p21(Cip1) expression. This resistance is associated with the interferon regulatory factor 1 (IRF-1) pathway, impacting cell cycle progression.
Area of Science:
- Oncology
- Molecular Biology
- Cell Cycle Regulation
Background:
- UCN-01 (7-hydroxystaurosporine) is a potent inhibitor of malignant cell growth.
- Understanding resistance mechanisms to UCN-01 is crucial for developing effective lung cancer therapies.
Purpose of the Study:
- To characterize a UCN-01-resistant human small cell lung carcinoma subline (SBC-3/UCN).
- To investigate the molecular mechanisms underlying UCN-01 resistance in lung cancer cells.
Main Methods:
- Establishment and characterization of SBC-3/UCN cell line.
- Analysis of cell cycle progression (G1 accumulation), protein expression (phosphorylated RB, p21(Cip1)), and kinase activity (CDK2, CDK4, CDK6).
- Screening of cell cycle regulatory molecules, including interferon regulatory factor 1 (IRF-1).
Main Results:
- SBC-3/UCN cells exhibited 8-fold greater resistance to UCN-01 compared to parent SBC-3 cells.
- UCN-01 resistance was associated with absent G1 accumulation, decreased phosphorylated RB, and lack of p21(Cip1) induction.
- UCN-01 failed to inhibit CDK2 activity in SBC-3/UCN cells, which showed higher CDK6 activity.
- A significant decrease in IRF-1 expression was observed in SBC-3/UCN cells.
Conclusions:
- The IRF-1 pathway and its role in p21(Cip1) induction are critical determinants of UCN-01-induced growth inhibition in lung cancer.
- Dysregulation of the IRF-1/p21(Cip1) axis contributes to UCN-01 resistance in small cell lung carcinoma.